Nevrox
Therapeutic Small Molecule Inhibitor for Treating Neurodegenerative Disorders
Health Tech & Life Sciences
Non Active, Sep 2022 ceased to operate
Company Overview
Snapshot
Founded in July 2019 by Niva Segev-Amzaleg and Brent Stockwell, Nevrox operated with 1–10 employees. The company secured funding across one round from two investors. Nevrox ceased operations in September 2022.
Business overview
Nevrox is a drug discovery company focused on developing a neuroprotective small molecule modulator of protein disulfide isomerase (PDI). This technology is aimed at treating neurodegenerative disorders such as Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). The company operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and drug discovery industries with its B2B business model.
Log in to access full profile ›Company Intelligence Q&A
- What is Nevrox's primary focus?
- Nevrox is a drug discovery company dedicated to developing a neuroprotective small molecule modulator of protein disulfide isomerase (PDI) for the treatment of neurodegenerative disorders.
- Which diseases does Nevrox's technology aim to treat?
- Nevrox's technology is focused on treating Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
- When was Nevrox founded?
- Nevrox was founded in July 2019.
- Who are the founders of Nevrox?
- The founders of Nevrox are Niva Segev-Amzaleg and Brent Stockwell.
- When did Nevrox cease operations?
- Nevrox ceased to operate in September 2022.